R is increasingly used in the pharmaceutical industry as the backbone for the pan-study codebase for the design and analysis of clinical trials. In parallel with this shift to R, many companies are open sourcing, and collaborating, on the post-competitive code used across studies. While numerous benefits come from companies open sourcing their R codebase, from better talent acquisition, to transparency with regulators, activity on git repos provides an insight into the return on investment (ROI) from external contributions to the codebase a company depends on. In this talk I share examples of how the Github API and git history can be leveraged to assess external contributions to the late-stage codebase Roche open-sourced, shedding light on the tangible benefits derived from collaborative development in an open setting.